- Home
- ABTS vs KZIA Comparison
ABTS vs KZIA Comparison
Compare ABTS & KZIA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ABTS | KZIA |
|---|---|---|
| Founded | 2010 | 1994 |
| Country | Hong Kong | Australia |
| Employees | N/A | N/A |
| Industry | Computer Software: Programming Data Processing | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 14.1M | 161.5M |
| IPO Year | N/A | 1999 |
Fundamental Metrics
Financial Performance| Metric | ABTS | KZIA |
|---|---|---|
| Price | $5.72 | $9.70 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $17.67 |
| AVG Volume (30 Days) | 18.8K | ★ 292.8K |
| Earning Date | 08-13-2025 | 12-26-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $7,384,971.00 | $1,199,108.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 22.52 | N/A |
| 52 Week Low | $1.35 | $2.86 |
| 52 Week High | $14.10 | $17.40 |
Technical Indicators
Market Signals| Indicator | ABTS | KZIA |
|---|---|---|
| Relative Strength Index (RSI) | 46.73 | 48.49 |
| Support Level | $5.30 | $8.91 |
| Resistance Level | $6.07 | $12.20 |
| Average True Range (ATR) | 0.43 | 2.24 |
| MACD | -0.02 | -0.45 |
| Stochastic Oscillator | 29.17 | 12.84 |
Price Performance
Historical ComparisonAbout ABTS Abits Group Inc
Abits Group Inc is a digital data center operator with bitcoin self-mining operations. The group has its subsidiaries in USA, China, Canada and Hong Kong.
About KZIA Kazia Therapeutics Limited
Kazia Therapeutics Ltd is a biotechnology company focused on pharmaceutical drug development in oncology. The company has a portfolio of development candidates across various technologies targeting multiple cancer indications. Its primary program is Paxalisib, an investigational brain-penetrant inhibitor of the PI3K/Akt/mTOR pathway, designed for the treatment of brain cancer. The company develops targeted therapies aimed at addressing medical needs in oncology. The company operates in Australia and the United States.